# A PROSPECTIVE AND COMPARATIVE STUDY OF THE (COST) EFFECTIVENESS OF TENSION FREE VAGINAL MESH PLUS MONOCRYL (PROLIFT+MTM) VERSUS CONVENTIONAL VAGINAL PROLAPSE SURGERY IN PRIMARY PROLAPSE

Published: 29-07-2010 Last updated: 03-05-2024

To compare the clinical and cost effectiveness of the Tension free Vaginal Mesh + Monocryl (Prolift+MTM) with the standard vaginal prolapse surgery (i.e. fascial placation). A secondary objective is to track the post-operative and long-term...

**Ethical review** Approved WMO **Status** Recruiting

**Health condition type** Obstetric and gynaecological therapeutic procedures

**Study type** Interventional

## Summary

#### ID

NL-OMON35003

**Source** 

**ToetsingOnline** 

**Brief title** VROUW 2

#### Condition

Obstetric and gynaecological therapeutic procedures

#### **Synonym**

pelvic organ prolapse

#### Research involving

1 - A PROSPECTIVE AND COMPARATIVE STUDY OF THE (COST) EFFECTIVENESS OF TENSION FREE ... 25-05-2025

Human

**Sponsors and support** 

**Primary sponsor:** Universitair Medisch Centrum Sint Radboud

Source(s) of monetary or material Support: Ministerie van OC&W, Johnson & Johnson

Pharmaceutical

Intervention

**Keyword:** complications, efficacy, mesh, pelvic organ prolapse

**Outcome measures** 

**Primary outcome** 

The main outcome is the percentage of patients with objective anatomical

success (POP stage <2) after 24 months.

**Secondary outcome** 

As secondary outcome the subjective improvement in quality of life will be

measured by generic (EQ-5D) and disease-specific (UDI, DDI, IIQ and PFDI20)

quality of life instrument. Sexual functioning will be measured by generic

(FSFI) and disease specific (PISQ12) questionnaires. Complications will be

monitored with special notice for pain (Mc Gill pain questionnaire) Recovery

will be measured with the Recovery index 10. The economical endpoint is short

term (2 year) incremental cost-effectiveness in terms of costs per additional

year free of prolapse and costs per QALY gained.

**Study description** 

**Background summary** 

Pelvic organ prolapse is highly prevalent in the female population. The incidence of pelvic organ prolapse increases with age, so the longer life

2 - A PROSPECTIVE AND COMPARATIVE STUDY OF THE (COST) EFFECTIVENESS OF TENSION FREE ...

25-05-2025

expectancy of women may cause pelvic organ prolapse to become an even more major health issue. The recurrence rate of pelvic organ prolapse after surgical treatment is high. The recurrence rate of the anterior vaginal wall prolapse after an anterior colporrhaphy is 30%-45%. The posterior vaginal wall prolapse recurrence rate after a posterior colporrhaphy is 12-25%. This emphasizes the clinical need for improvement of the surgical techniques currently used. Placement of a mesh aims at reducing the recurrence rate (2-11%).

#### Study objective

To compare the clinical and cost effectiveness of the Tension free Vaginal Mesh + Monocryl (Prolift+MTM) with the standard vaginal prolapse surgery (i.e. fascial placation). A secondary objective is to track the post-operative and long-term complications of both procedures. A third objective is to evaluate recovery after surgery

#### Study design

This study is a prospective, multicentre, randomized, non-blinded study between Tension free Vaginal Mesh + Monocryl (Prolift+MTM) and standard vaginal prolapse surgery (i.e. fascial plication).

#### Intervention

Prolapse surgery with tension free vaginal mesh + Monocryl (Prolift + M) versus conventional vaginal prolapse surgery.

#### Study burden and risks

Burden associated with participation: complete a disease specific Quality of life questionnaire 4 times, complete a recovery index questionnaire 3 times. Visit the hospital 4 times after the surgery (this is 2 times more often than patients not participating in the study)

Since subjects are selected from subjects already agreeing to complete a surgical procedure, the additional risks of participation in this study are low.

These risks include tissue erosion (vaginal, rectal or bladder), vaginal pain/dyspareunia.

## **Contacts**

#### **Public**

Geert Grooteplein-Zuid 14 6525 GA Nijmegen NL

#### Scientific

Universitair Medisch Centrum Sint Radboud

Geert Grooteplein-Zuid 14 6525 GA Nijmegen NL

## **Trial sites**

#### **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years) Elderly (65 years and older)

#### Inclusion criteria

primary pelvic organ prolapse (anterior and/or posterior compartment) POP stage II or more age >44 years

#### **Exclusion criteria**

pregnancy
age < 45 years
previous prolapse surgery
blood coagulation disorders
a compromised immune system or any other conditions that would compromise healing
unwilling or unable to return for evaluation
Previous irradiation
Presence of any malignancy

# Study design

## **Design**

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: Active

Primary purpose: Treatment

#### Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 19-01-2011

Enrollment: 176

Type: Actual

## **Ethics review**

Approved WMO

Date: 29-07-2010

Application type: First submission

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Approved WMO

Date: 14-11-2011

Application type: Amendment

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Red	gister	ID	
,	,		

Other dit protocol wordt binnenkort geregistreerd in clinicaltrials.gov

CCMO NL31706.091.10